87 related articles for article (PubMed ID: 12209981)
1. Prognostic significance of cytokine modulation in non-small cell lung cancer.
Neuner A; Schindel M; Wildenberg U; Muley T; Lahm H; Fischer JR
Int J Cancer; 2002 Sep; 101(3):287-92. PubMed ID: 12209981
[TBL] [Abstract][Full Text] [Related]
2. Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer.
Neuner A; Schindel M; Wildenberg U; Muley T; Lahm H; Fischer JR
Lung Cancer; 2001 Dec; 34 Suppl 2():S79-82. PubMed ID: 11720746
[TBL] [Abstract][Full Text] [Related]
3. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer.
Koh E; Iizasa T; Yamaji H; Sekine Y; Hiroshima K; Yoshino I; Fujisawa T
Int J Surg Pathol; 2012 Jun; 20(3):233-9. PubMed ID: 22334615
[TBL] [Abstract][Full Text] [Related]
4. Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non-small cell lung cancer.
Pei BX; Sun BS; Zhang ZF; Wang AL; Ren P
J Thorac Cardiovasc Surg; 2014 Oct; 148(4):1208-1216.e2. PubMed ID: 24907005
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients.
Carlini MJ; Roitman P; Nuñez M; Pallotta MG; Boggio G; Smith D; Salatino M; Joffé ED; Rabinovich GA; Puricelli LI
Lung Cancer; 2014 Apr; 84(1):73-8. PubMed ID: 24560493
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
7. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.
Soria JC; Moon C; Kemp BL; Liu DD; Feng L; Tang X; Chang YS; Mao L; Khuri FR
Clin Cancer Res; 2003 May; 9(5):1785-91. PubMed ID: 12738735
[TBL] [Abstract][Full Text] [Related]
8. Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer.
Fischer JR; Schindel M; Bülzebruck H; Lahm H; Krammer PH; Drings P
Ann Oncol; 1997 May; 8(5):457-61. PubMed ID: 9233525
[TBL] [Abstract][Full Text] [Related]
9. The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer.
Li J; Zhang JT; Jiang X; Shi X; Shen J; Feng F; Chen J; Liu G; He P; Jiang J; Tsang LL; Wang Y; Rosell R; Jiang L; He J; Chan HC
Int J Oncol; 2015 May; 46(5):2107-15. PubMed ID: 25760446
[TBL] [Abstract][Full Text] [Related]
10. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
12. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value study of lung cancer molecular markers].
García Luján R; Conde Gallego E; López Ríos F; Martín De Nicolás JL; Sánchez Céspedes M; García Quero C; López Encuentra A
Med Clin (Barc); 2009 Apr; 132(14):529-36. PubMed ID: 19368933
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3796-802. PubMed ID: 12473592
[TBL] [Abstract][Full Text] [Related]
15. LncRNA HMlincRNA717 is down-regulated in non-small cell lung cancer and associated with poor prognosis.
Xie X; Liu HT; Mei J; Ding FB; Xiao HB; Hu FQ; Hu R; Wang MS
Int J Clin Exp Pathol; 2014; 7(12):8881-6. PubMed ID: 25674259
[TBL] [Abstract][Full Text] [Related]
16. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
[TBL] [Abstract][Full Text] [Related]
17. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung.
Anton RC; Coffey DM; Gondo MM; Stephenson MA; Brown RW; Cagle PT
Mod Pathol; 2000 Nov; 13(11):1167-72. PubMed ID: 11106072
[TBL] [Abstract][Full Text] [Related]
18. Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer.
Zhang Q; Wang J; Zhang H; Zhao D; Zhang Z; Zhang S
J Cancer Res Ther; 2015; 11(1):223-8. PubMed ID: 25879366
[TBL] [Abstract][Full Text] [Related]
19. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer.
Silva EM; Mariano VS; Pastrez PRA; Pinto MC; Castro AG; Syrjanen KJ; Longatto-Filho A
PLoS One; 2017; 12(7):e0181125. PubMed ID: 28715437
[TBL] [Abstract][Full Text] [Related]
20. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
